A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of AZD8330 in Patients With Advanced Malignancies.
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2011
At a glance
- Drugs AZD 8330 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 14 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Dec 2010 Planned end date changed from 1 Dec 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 12 May 2009 Planned end date changed from 1 Nov 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.